Perinatal use of aripiprazole: Plasma levels, placental transfer, and child outcome in 3 new cases

Journal of Clinical Psychopharmacology

Volumn 34, Issue 5, 2014, Pages 637-641

  Windhager, Elmar ^a   Kim, Sung Wan ^b   Saria, Alois ^c   Zauner, Katharina ^a   Amminger, Paul G ^d,e   Klier, Claudia M ^f  

^a Klinikum Wels Grieskirchen GmbH   (Austria)

^b Chonnam National University Medical School   (South Korea)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Departments of Child and Adolescent Psychiatry   (Australia)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

aripiprazole; placental transfer; plasma level; pregnancy; schizophrenia; therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; OLANZAPINE; PROLACTIN; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT DISORDER; CASE REPORT; CESAREAN SECTION; CHILDBIRTH; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIP DYSPLASIA; HUMAN; MENSTRUATION DISORDER; MONOTHERAPY; NEWBORN; OUTCOME ASSESSMENT; PERINATAL CARE; PERINATAL DRUG EXPOSURE; PHYSIOTHERAPY; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PUERPERIUM; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; TANDEM MASS SPECTROMETRY; TERATOGENESIS; TERATOGENICITY; VAGINAL DELIVERY; WEIGHT GAIN; BLOOD; DRUG EFFECTS; METABOLISM; PLACENTA; PREGNANCY;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; FEMALE; HUMANS; PLACENTA; PREGNANCY; PREGNANCY OUTCOME;

EID: 84907003762     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000171     Document Type: Article

References (36)

1. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444-449.
2. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013;16:149-157.
3. Potkin SG, Anutosh RS, Kujawa, MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681-690.
4. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164:1404-1410.
5. Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192:333-337.
6. Kulkarni J, McCauley-Elsom K, Marston N, et al. Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy. Aust N Z J Psychiatry. 2008;42:38-44.
7. Koren G. Treating the mother, protecting the unborn: the motherisk approach. J Pediatr Pharmacol Ther. 2013;18:47
8. Schaefer C, Oppermann M, Wacker E, et al. Drug safety in pregnancyVthe Embryotox project. Z Evid Fortbild Qual Gesundhwes. 2012;106:723-728.
9. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66:695-705.
10. McCauley-Elsom K, Gurvich C, Elsom SJ, et al. Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs. 2010;17:97-104.
11. Johnson KC, LaPrairie JL, Brennan PA, et al. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69:787-794.
12. Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother. 2006;40:575.
13. Doulgeraki G, Karadima D, Kalogiratos G, et al.. Pregnancy, aripiprazole and psychotherapy (abstract). Eur Psychiatry. 2007;22(suppl 1):S206.
14. Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health. 2008;11:249-250.
15. Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009;12:53-57.
16. Lutz UC, Hiemke C, Wiatr G, et al. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol. 2010;30:204-205.
17. Gentile S, Tofani S, Bellantuono C. Aripiprazole and pregnancy: a case report and literature review. J Clin Psychopharmacol. 2011;31:531-532.
18. Watanabe N, Kasahara M, Sugibayashi R, et al. Perinatal use of aripiprazole: a case report. J Clin Psychopharmacol. 2011;31:377-379.
19. Nguyen T, Teoh S, Hackett LP, et al. Placental transfer of aripiprazole. Aust N Z J Psychiatry. 2011;45:500-501.
20. Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: a case report. Pharmacopsychiatry. 2012;45:299-300.
21. Derganc M, Savs AP. The use of Aripiprazole in pregnancy: a case report. Abstract PO02 at the 21st European Congress of Psychiatry EPA, April 6Y9, 2013; Nice, France.
22. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33:453-462.
23. Bodén R, Lundgren M, Brandt L, et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.
24. Raha S, Taylor VH, Holloway AC. Effect of atypical antipsychotics on fetal growth: is the placenta involved? J Pregnancy. 2012;2012:315203.
25. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162:79-91.
26. Kirschbaum KM, Muller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem. 2005;51:1718-1721.
27. Gründer G, Hippius H, Carlsson A. The "atypicality" of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8:197-202.
28. Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazoleVdose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71:1447-1456.
29. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
30. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry. 2008;165:988-995.
31. Yaeger D, Smith HG, Altshuler LL. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. Am J Psychiatry. 2006;163:2064-2070.
32. Tracy TS, Venkataramanan R, Glover DD, et al.. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633-639.
33. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161:1324-1333.
34. Kirschbaum KM, Muller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9:212-218.
35. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214-1220.
36. Robinson GE. Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol. 2012;19:e380-e386.